RxDoctor Payments Data

David Sisul, MD

Urology · la Grande, ORNPI 1306000690

Payments from drug & device makers

$2,539in general payments, 2019–2025

Across 94 payments — averaging $27.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$585
  • Astellas Pharma US Inc$468
  • Endo Pharmaceuticals Inc.$280
  • Olympus America Inc.$208
  • AbbVie$164
  • Procept Biorobotics Corporation$125
  • plus $707 from 20 others

What the payments were for

  • Food & beverage$2,19286%
  • Education$34714%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,539 in reported general payments places this provider in the 55th percentile of 153 urology providers in Oregon.

See all urology providers in Oregon

Medicare billing

Part B allowed, 2024
$32,326
Medicare patients
72
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix11$29,583
GemtesaVibegron42$29,460
Solifenacin Succinate174$26,656
MyrbetriqMirabegron48$25,080
Tamsulosin Hcl424$3,271
Tolterodine Tartrate ErTolterodine Tartrate20$2,029
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst79$1,396
Testosterone Cypionate36$1,102
Finasteride133$938
Bicalutamide14$779
Cefdinir12$701
Trimethoprim12$606
Estradiol12$551
Methenamine Hippurate20$477
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav33$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$71$59,04353 claims
Astellas Pharma US IncMyrbetriq$468$25,08048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 153 urology providers in Oregon.

Other urology in la Grande

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →